BACKGROUND: Gamma-aminobutyric acid (GABA) has been reported to inhibit the growth of cholangiocarcinoma QBC939 cells, but the mechanisms are still not fully understood. AIMS: To explore the mechanisms of the anti-cancer effect of GABA on QBC939 cells. METHODS: An initial immunohistochemistry study of the expressions of GABA receptors in cholangiocarcinoma tissues was followed by the culture and treatment of QBC939 cells for 48 h with GABA, GABA + bicuculine (GABAA receptor antagonist), GABA + phaclofen (GABAB receptor antagonist), and GABA + AG490 (Janus Kinase inhibitor). MTT and Annexin V-FITC/PI binding assays were used to determine the proliferation and apoptosis of the QBC939 cells. The expression of the signal transducer and activator of transcription 3 (STAT3) and phosphorylated STAT3 (Tyr705) [p-STAT3 (Tyr705)] was evaluated by the western blot assay. The effect of GABA on the growth of QBC939 xenograft tumors in athymic nu/nu mice was examined, and p-STAT3 (Tyr705) expression in xenograft tumors was detected by immunohistochemistry. RESULTS: A significant difference was only observed in GABAB receptor expression between cholangiocarcinoma and normal bile tissues. The MTT and Annexin V-FITC/PI assays showed that the antiproliferative and proapoptotic effects of GABA on QBC939 cells could be antagonized by phaclofen and AG490, but not bicuculine. GABA significantly down-regulated p-STAT3 (Tyr705) expression; this action was also antagonized by phaclofen and AG490. GABA also effectively inhibited xenograft tumor growth, and p-STAT3 (Tyr705) expression was significantly decreased in GABA-treated xenograft tumors. CONCLUSIONS: GABA may inhibit the growth of cholangiocarcinoma QBC939 cells through the GABAB receptor, and the anti-cancer effects may be partly mediated via the JAK/STAT3 pathway.
BACKGROUND:Gamma-aminobutyric acid (GABA) has been reported to inhibit the growth of cholangiocarcinoma QBC939 cells, but the mechanisms are still not fully understood. AIMS: To explore the mechanisms of the anti-cancer effect of GABA on QBC939 cells. METHODS: An initial immunohistochemistry study of the expressions of GABA receptors in cholangiocarcinoma tissues was followed by the culture and treatment of QBC939 cells for 48 h with GABA, GABA + bicuculine (GABAA receptor antagonist), GABA + phaclofen (GABAB receptor antagonist), and GABA + AG490 (Janus Kinase inhibitor). MTT and Annexin V-FITC/PI binding assays were used to determine the proliferation and apoptosis of the QBC939 cells. The expression of the signal transducer and activator of transcription 3 (STAT3) and phosphorylated STAT3 (Tyr705) [p-STAT3 (Tyr705)] was evaluated by the western blot assay. The effect of GABA on the growth of QBC939 xenograft tumors in athymic nu/nu mice was examined, and p-STAT3 (Tyr705) expression in xenograft tumors was detected by immunohistochemistry. RESULTS: A significant difference was only observed in GABAB receptor expression between cholangiocarcinoma and normal bile tissues. The MTT and Annexin V-FITC/PI assays showed that the antiproliferative and proapoptotic effects of GABA on QBC939 cells could be antagonized by phaclofen and AG490, but not bicuculine. GABA significantly down-regulated p-STAT3 (Tyr705) expression; this action was also antagonized by phaclofen and AG490. GABA also effectively inhibited xenograft tumor growth, and p-STAT3 (Tyr705) expression was significantly decreased in GABA-treated xenograft tumors. CONCLUSIONS:GABA may inhibit the growth of cholangiocarcinoma QBC939 cells through the GABAB receptor, and the anti-cancer effects may be partly mediated via the JAK/STAT3 pathway.
Authors: Peramaiyan Rajendran; Feng Li; Muthu K Shanmugam; Radhamani Kannaiyan; Jen Nee Goh; Kwong Fai Wong; Wei Wang; Ester Khin; Vinay Tergaonkar; Alan Prem Kumar; John M Luk; Gautam Sethi Journal: Cancer Prev Res (Phila) Date: 2012-02-27
Authors: Giorgio Inghirami; Roberto Chiarle; William J Simmons; Roberto Piva; Karni Schlessinger; David E Levy Journal: Cell Cycle Date: 2005-09-30 Impact factor: 4.534
Authors: Premal H Thaker; Kenji Yokoi; Nicholas B Jennings; Yang Li; Robert B Rebhun; Dennis L Rousseau; Dominic Fan; Anil K Sood Journal: Cancer Biol Ther Date: 2005-07-09 Impact factor: 4.742
Authors: Takahiro Sato; Lynn Moretti Neilson; Amy R Peck; Chengbao Liu; Thai H Tran; Agnes Witkiewicz; Terry Hyslop; Marja T Nevalainen; Guido Sauter; Hallgeir Rui Journal: Am J Cancer Res Date: 2011 Impact factor: 6.166
Authors: A Knuth; H Gabbert; W Dippold; O Klein; W Sachsse; D Bitter-Suermann; W Prellwitz; K H Meyer zum Büschenfelde Journal: J Hepatol Date: 1985 Impact factor: 25.083
Authors: Boris R A Blechacz; Rory L Smoot; Steven F Bronk; Nathan W Werneburg; Alphonse E Sirica; Gregory J Gores Journal: Hepatology Date: 2009-12 Impact factor: 17.425